{"id":13126,"date":"2023-11-30T20:51:24","date_gmt":"2023-12-01T01:51:24","guid":{"rendered":"https:\/\/sliceofhealthcare.com\/?p=13126"},"modified":"2023-11-30T22:43:25","modified_gmt":"2023-12-01T03:43:25","slug":"aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines","status":"publish","type":"post","link":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/","title":{"rendered":"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"13126\" class=\"elementor elementor-13126\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-53265ad elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"53265ad\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b1fd0d8\" data-id=\"b1fd0d8\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-219a45b elementor-widget elementor-widget-heading\" data-id=\"219a45b\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 id=\"key-highlights\" class=\"elementor-heading-title elementor-size-default\">Key Highlights<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ea205cb elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"ea205cb\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-37761df\" data-id=\"37761df\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6d09b4b elementor-widget elementor-widget-text-editor\" data-id=\"6d09b4b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>Aro Biotherapeutics raised $41.5M<\/strong>\u00a0in a Series B funding round led by Cowen Healthcare Investments.<\/li><li><strong>Funding participants include<\/strong>\u00a0Johnson &amp; Johnson Innovation \u2013 JJDC, Inc., Northpond Ventures, Healthcap, and BVF Partners, L.P.<\/li><li><strong>Focus on advancing ABX1100<\/strong>, a novel treatment for Pompe Disease, with anticipated initial study data in 2024.<\/li><\/ul><p><b>Source:\u00a0<\/b><a href=\"https:\/\/www.businesswire.com\/news\/home\/20231128072316\/en\/Aro-Biotherapeutics-Secures-41.5M-Series-B-Financing\">Business Wire<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-e90ba87 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"e90ba87\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-0c976b7\" data-id=\"0c976b7\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5516a40 elementor-widget elementor-widget-heading\" data-id=\"5516a40\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 id=\"notable-quote\" class=\"elementor-heading-title elementor-size-default\">Notable Quote<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-d697cb9 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"d697cb9\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-0a4aada\" data-id=\"0a4aada\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-91b3c7e elementor-widget elementor-widget-text-editor\" data-id=\"91b3c7e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>&#8220;We are appreciative of the support provided by this syndicate of leading life science industry investors. Aro is well positioned to advance our pipeline and progress the field by leveraging our Centyrin platform to enable efficient and tissue-targeted delivery of siRNA. This funding enables us to continue to pursue our mission and bring new medicines to patients who desperately need more effective treatments.,&#8221;<b> &#8211; Susan Dillon, Ph.D., Chief Executive Officer at Aro<\/b><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-de5db98 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"de5db98\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-49139f5\" data-id=\"49139f5\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-416ad5a elementor-widget elementor-widget-heading\" data-id=\"416ad5a\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 id=\"sohs-take\" class=\"elementor-heading-title elementor-size-default\">SoH's Take<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-815da73 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no\" data-id=\"815da73\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-123f65b\" data-id=\"123f65b\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e1455ae elementor-widget elementor-widget-text-editor\" data-id=\"e1455ae\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"post_body_wrapper\"><div class=\"post-body-container\"><div class=\"post-body-renderer-component post_body\"><div class=\"post-body-content\"><div class=\"body_text redactor-styles redactor-in\"><p>The recent funding secured by Aro Biotherapeutics is a significant milestone in the biotechnology sector, especially in the development of tissue-targeted genetic medicines. This Series B round not only reflects the industry&#8217;s confidence in Aro&#8217;s innovative approach and potential in treating diseases like Pompe Disease but also underscores the growing interest in targeted genetic therapies. The involvement of renowned investors and leaders in the life sciences industry further validates the potential of Aro&#8217;s Centyrin platform and its upcoming projects. The progress of ABX1100, particularly, will be closely monitored as it holds promise for addressing unmet needs in the treatment of Pompe Disease. This funding round could mark a pivotal moment for Aro Biotherapeutics in establishing itself as a leader in the field of targeted genetic medicine.<\/p><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"Key Highlights Aro Biotherapeutics raised $41.5M\u00a0in a Series B funding round led by Cowen Healthcare Investments. Funding participants&hellip;\n","protected":false},"author":14,"featured_media":13127,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pgc_sgb_lightbox_settings":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1916,1896],"tags":[2746,2750,2747,2749,2587,2748],"class_list":["post-13126","post","type-post","status-publish","format-standard","has-post-thumbnail","category-funding-news","category-news","tag-aro-biotherapeutics","tag-bvf-partners","tag-cowen-healthcare-investments","tag-healthcap","tag-johnson-johnson-innovation","tag-northpond-ventures","cs-entry","cs-video-wrap"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.6 (Yoast SEO v24.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines<\/title>\n<meta name=\"description\" content=\"Aro Biotherapeutics announces a significant $41.5M Series B funding round led by Cowen Healthcare Investments, with participation from Johnson &amp; Johnson Innovation \u2013 JJDC, Inc., and others. The funding accelerates the development of novel genetic treatments including ABX1100 for Pompe Disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines\" \/>\n<meta property=\"og:description\" content=\"Aro Biotherapeutics announces a significant $41.5M Series B funding round led by Cowen Healthcare Investments, with participation from Johnson &amp; Johnson Innovation \u2013 JJDC, Inc., and others. The funding accelerates the development of novel genetic treatments including ABX1100 for Pompe Disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/\" \/>\n<meta property=\"og:site_name\" content=\"Slice of Healthcare\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-01T01:51:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-01T03:43:25+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Chris-Anne Roque\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SliceofHC\" \/>\n<meta name=\"twitter:site\" content=\"@SliceofHC\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Chris-Anne Roque\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/\"},\"author\":{\"name\":\"Chris-Anne Roque\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/3e92e4d38084087254b8ad198e76e6ca\"},\"headline\":\"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines\",\"datePublished\":\"2023-12-01T01:51:24+00:00\",\"dateModified\":\"2023-12-01T03:43:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/\"},\"wordCount\":273,\"publisher\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png?fit=1280%2C720&ssl=1\",\"keywords\":[\"Aro Biotherapeutics\",\"BVF Partners\",\"Cowen Healthcare Investments\",\"Healthcap\",\"Johnson &amp; Johnson Innovation\",\"Northpond Ventures\"],\"articleSection\":[\"Funding News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/\",\"url\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/\",\"name\":\"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines\",\"isPartOf\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png?fit=1280%2C720&ssl=1\",\"datePublished\":\"2023-12-01T01:51:24+00:00\",\"dateModified\":\"2023-12-01T03:43:25+00:00\",\"description\":\"Aro Biotherapeutics announces a significant $41.5M Series B funding round led by Cowen Healthcare Investments, with participation from Johnson & Johnson Innovation \u2013 JJDC, Inc., and others. The funding accelerates the development of novel genetic treatments including ABX1100 for Pompe Disease.\",\"breadcrumb\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png?fit=1280%2C720&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png?fit=1280%2C720&ssl=1\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sliceofhealthcare.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#website\",\"url\":\"https:\/\/sliceofhealthcare.com\/\",\"name\":\"Slice of Healthcare\",\"description\":\"Redefining Healthcare Media.\",\"publisher\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sliceofhealthcare.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#organization\",\"name\":\"Slice of Healthcare\",\"url\":\"https:\/\/sliceofhealthcare.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2022\/02\/New-large-logo-for-slice-of-healthcare-website-2x-160-%C3%97-160-px.png?fit=160%2C160&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2022\/02\/New-large-logo-for-slice-of-healthcare-website-2x-160-%C3%97-160-px.png?fit=160%2C160&ssl=1\",\"width\":160,\"height\":160,\"caption\":\"Slice of Healthcare\"},\"image\":{\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/SliceofHC\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/3e92e4d38084087254b8ad198e76e6ca\",\"name\":\"Chris-Anne Roque\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3175699e8136e462915e1ca2c0407ee6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3175699e8136e462915e1ca2c0407ee6?s=96&d=mm&r=g\",\"caption\":\"Chris-Anne Roque\"},\"url\":\"https:\/\/sliceofhealthcare.com\/author\/anne\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines","description":"Aro Biotherapeutics announces a significant $41.5M Series B funding round led by Cowen Healthcare Investments, with participation from Johnson & Johnson Innovation \u2013 JJDC, Inc., and others. The funding accelerates the development of novel genetic treatments including ABX1100 for Pompe Disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/","og_locale":"en_US","og_type":"article","og_title":"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines","og_description":"Aro Biotherapeutics announces a significant $41.5M Series B funding round led by Cowen Healthcare Investments, with participation from Johnson & Johnson Innovation \u2013 JJDC, Inc., and others. The funding accelerates the development of novel genetic treatments including ABX1100 for Pompe Disease.","og_url":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/","og_site_name":"Slice of Healthcare","article_published_time":"2023-12-01T01:51:24+00:00","article_modified_time":"2023-12-01T03:43:25+00:00","og_image":[{"width":1280,"height":720,"url":"http:\/\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png","type":"image\/png"}],"author":"Chris-Anne Roque","twitter_card":"summary_large_image","twitter_creator":"@SliceofHC","twitter_site":"@SliceofHC","twitter_misc":{"Written by":"Chris-Anne Roque","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#article","isPartOf":{"@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/"},"author":{"name":"Chris-Anne Roque","@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/3e92e4d38084087254b8ad198e76e6ca"},"headline":"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines","datePublished":"2023-12-01T01:51:24+00:00","dateModified":"2023-12-01T03:43:25+00:00","mainEntityOfPage":{"@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/"},"wordCount":273,"publisher":{"@id":"https:\/\/sliceofhealthcare.com\/#organization"},"image":{"@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png?fit=1280%2C720&ssl=1","keywords":["Aro Biotherapeutics","BVF Partners","Cowen Healthcare Investments","Healthcap","Johnson &amp; Johnson Innovation","Northpond Ventures"],"articleSection":["Funding News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/","url":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/","name":"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines","isPartOf":{"@id":"https:\/\/sliceofhealthcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#primaryimage"},"image":{"@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png?fit=1280%2C720&ssl=1","datePublished":"2023-12-01T01:51:24+00:00","dateModified":"2023-12-01T03:43:25+00:00","description":"Aro Biotherapeutics announces a significant $41.5M Series B funding round led by Cowen Healthcare Investments, with participation from Johnson & Johnson Innovation \u2013 JJDC, Inc., and others. The funding accelerates the development of novel genetic treatments including ABX1100 for Pompe Disease.","breadcrumb":{"@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#primaryimage","url":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png?fit=1280%2C720&ssl=1","contentUrl":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png?fit=1280%2C720&ssl=1","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/sliceofhealthcare.com\/aro-biotherapeutics-secures-41-5m-in-series-b-funding-to-advance-tissue-targeted-genetic-medicines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sliceofhealthcare.com\/"},{"@type":"ListItem","position":2,"name":"Aro Biotherapeutics Secures $41.5M in Series B Funding to Advance Tissue-Targeted Genetic Medicines"}]},{"@type":"WebSite","@id":"https:\/\/sliceofhealthcare.com\/#website","url":"https:\/\/sliceofhealthcare.com\/","name":"Slice of Healthcare","description":"Redefining Healthcare Media.","publisher":{"@id":"https:\/\/sliceofhealthcare.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sliceofhealthcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/sliceofhealthcare.com\/#organization","name":"Slice of Healthcare","url":"https:\/\/sliceofhealthcare.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2022\/02\/New-large-logo-for-slice-of-healthcare-website-2x-160-%C3%97-160-px.png?fit=160%2C160&ssl=1","contentUrl":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2022\/02\/New-large-logo-for-slice-of-healthcare-website-2x-160-%C3%97-160-px.png?fit=160%2C160&ssl=1","width":160,"height":160,"caption":"Slice of Healthcare"},"image":{"@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/SliceofHC"]},{"@type":"Person","@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/3e92e4d38084087254b8ad198e76e6ca","name":"Chris-Anne Roque","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sliceofhealthcare.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3175699e8136e462915e1ca2c0407ee6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3175699e8136e462915e1ca2c0407ee6?s=96&d=mm&r=g","caption":"Chris-Anne Roque"},"url":"https:\/\/sliceofhealthcare.com\/author\/anne\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/sliceofhealthcare.com\/wp-content\/uploads\/2023\/11\/Aro-Biotherapeutics-Secures-_41.5M-in-Series-B-Funding-to-Advance-Tissue-Targeted-Genetic-Medicines.png?fit=1280%2C720&ssl=1","jetpack-related-posts":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/posts\/13126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/comments?post=13126"}],"version-history":[{"count":5,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/posts\/13126\/revisions"}],"predecessor-version":[{"id":13175,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/posts\/13126\/revisions\/13175"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/media\/13127"}],"wp:attachment":[{"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/media?parent=13126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/categories?post=13126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sliceofhealthcare.com\/wp-json\/wp\/v2\/tags?post=13126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}